Trials / Recruiting
RecruitingNCT07241767
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
An Open Label, Multicenter Phase II Clinical Study on the Safety, Tolerability, and Efficacy of FH-006 Injection Combined With Other Anti-tumor Therapies in Lung Cancer Subjects
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin | FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin |
| DRUG | FH-006 ; SHR-1316 ; BP102 | FH-006 ; SHR-1316 ; BP102 |
| DRUG | FH-006; SHR-1316 ; SHR-8068 | FH-006; SHR-1316 ; SHR-8068 |
Timeline
- Start date
- 2025-11-12
- Primary completion
- 2027-11-01
- Completion
- 2028-11-01
- First posted
- 2025-11-21
- Last updated
- 2026-04-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07241767. Inclusion in this directory is not an endorsement.